Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 40,100
+400 (1.01%)
At close: Oct 30, 2026
KRX:317450 Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 585,460 | 1,005,940 | - | - | - | - | |
Market Cap Growth | -55.39% | - | - | - | - | - |
Enterprise Value | 116,441 | 532,289 | - | - | - | - |
Last Close Price | 39700.00 | 68146.17 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 6.24 | 12.35 | - | - | - | - |
PS Ratio | 1.98 | 3.50 | - | - | - | - |
PB Ratio | 0.71 | 1.27 | - | - | - | - |
P/TBV Ratio | 0.72 | 1.27 | - | - | - | - |
P/FCF Ratio | 18.23 | 19.52 | - | - | - | - |
P/OCF Ratio | 7.44 | 12.33 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.38 | 1.85 | - | - | - | - |
EV/EBITDA Ratio | 1.02 | 5.15 | - | - | - | - |
EV/EBIT Ratio | 1.13 | 5.76 | - | - | - | - |
EV/FCF Ratio | 3.48 | 10.33 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.01 | 0.01 | 0.03 | 0.04 | 0.06 | 0.07 |
Debt / FCF Ratio | 0.03 | 0.03 | 0.04 | 0.05 | 0.09 | 0.09 |
Net Debt / Equity Ratio | -0.57 | -0.64 | -0.48 | -0.39 | -0.32 | -0.31 |
Net Debt / EBITDA Ratio | -4.32 | -4.91 | -2.45 | -1.93 | -1.58 | -1.34 |
Net Debt / FCF Ratio | -14.75 | -9.87 | -3.54 | -2.57 | -2.39 | -1.82 |
Asset Turnover | 0.40 | 0.40 | 0.49 | 0.49 | 0.50 | 0.52 |
Inventory Turnover | 1.63 | 1.82 | 1.73 | 1.70 | 1.74 | 1.56 |
Quick Ratio | 10.80 | 12.52 | 7.28 | 6.37 | 5.76 | 4.52 |
Current Ratio | 12.40 | 13.93 | 8.65 | 7.85 | 7.15 | 5.71 |
Return on Equity (ROE) | 12.91% | 12.28% | 13.68% | 16.63% | 14.36% | 16.91% |
Return on Assets (ROA) | 8.31% | 8.12% | 10.51% | 10.52% | 10.53% | 11.41% |
Return on Invested Capital (ROIC) | 24.95% | 26.33% | 25.70% | 23.54% | 19.48% | 21.07% |
Return on Capital Employed (ROCE) | 12.00% | 11.60% | 17.30% | 17.30% | 17.40% | 19.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 16.03% | 8.09% | - | - | - | - |
FCF Yield | 5.49% | 5.12% | - | - | - | - |
Dividend Yield | 2.49% | 2.18% | - | - | - | - |
Payout Ratio | 24.65% | 13.75% | 8.15% | 30.06% | 19.50% | 23.43% |
Buyback Yield / Dilution | -23.40% | -8.23% | - | - | - | - |
Total Shareholder Return | -20.88% | -6.06% | - | - | - | - |